This grant proposes to determine the role of Interleukin 16 in accumulation and function of T regulatory cells. While IL-16 was originally described as a chemotactic factor for CD4+ T cells, in models of antigen-induced airway inflammation, it is a potent inhibitor of the Th2 response. Inhibition of Th2 inflammation can, in part, be explained by IL-16 binding to CD4 which uncouples CD4 from the TcR complex inhibiting antigen and allogeneic T cell activation and by selective chemoattraction of Th1 cells. However, in addition, our preliminary data demonstrate that IL-16 is selectively chemotactic for CD4+CD25+CTLA4+ T cells which fail to proliferate to anti-CD3 and which inhibit autologous T cells proliferation to anti-CD3 defining them as T regulatory cells. Unlike TGF-beta, IL-16 is sufficient to induce FoxP3 expression without a second signal. In addition, following 2 weeks of culture with IL-16+IL-2, NWNAT cells develop a CD4+ CD25+ neuropilin-1 + phenotype which correspond with T regulatory suppressor function. Last, we show that thymus and lung T cells from IL-16-/- mice are deficient in expression of CD25 on CD4 cells (CD4+CD25lo) and have fewer CD4+ CD25+ neuropilin-1+ T cells. Intratracheal administration of IL-16 corrects these abnormalities in CD4+CD25+ T cells in the lung in IL-16-/- mice, while thymus and splenic continue to contain CD4+CD25lo T cells and as predicted, IL-16-/- mice exhibit enhanced Th2 inflammation in the lung when challenged with OVA. Our overall hypothesis is that, in addition to its direct effects on TcR signaling, IL-16 also modulates Th2 type airway inflammation by chemoattraction and expansion of T regulatory cells.
Three aims will address this hypotheses by: 1. Determining the phenotype of T regulatory cells that migrate to IL-16 in comparison to T regulatory cells that migrate to TGF-beta; 2. Determining the phenotype and function of T regulatory cells expanded in vitro in response to IL-16; and 3. Demonstrating the function of IL-16 responsive T regulatory cells by introducing them in vivo in a mouse model of antigen-induced inflammation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI035680-12
Application #
7049545
Study Section
Lung Cellular, Molecular, and Immunobiology Study Section (LCMI)
Program Officer
Dong, Gang
Project Start
1994-12-01
Project End
2009-12-31
Budget Start
2006-01-01
Budget End
2006-12-31
Support Year
12
Fiscal Year
2006
Total Cost
$394,262
Indirect Cost
Name
Boston University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Croq, Francoise; Vizioli, Jacopo; Tuzova, Marina et al. (2010) A homologous form of human interleukin 16 is implicated in microglia recruitment following nervous system injury in leech Hirudo medicinalis. Glia 58:1649-62
Green, Daniel S; Center, David M; Cruikshank, William W (2009) Human immunodeficiency virus type 1 gp120 reprogramming of CD4+ T-cell migration provides a mechanism for lymphadenopathy. J Virol 83:5765-72
Zhang, Yujun; Tuzova, Marina; Xiao, Zhi-Xiong J et al. (2008) Pro-IL-16 recruits histone deacetylase 3 to the Skp2 core promoter through interaction with transcription factor GABP. J Immunol 180:402-8
Mashikian, M V; Tarpy, R E; Saukkonen, J J et al. (1998) Identification of IL-16 as the lymphocyte chemotactic activity in the bronchoalveolar lavage fluid of histamine-challenged asthmatic patients. J Allergy Clin Immunol 101:786-92
Center, D M; Kornfeld, H; Cruikshank, W W (1996) Interleukin 16 and its function as a CD4 ligand. Immunol Today 17:476-81